List of Excipients in Branded Drug GOLYTELY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	GOLYTELY	peg-3350 and electrolytes	54868-0054	WATER

GoLYTELY Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

GoLYTELY is a prescription bowel-preparation product built around polyethylene glycol 3350 and a balanced electrolyte system. Its commercial value does not depend on active-ingredient novelty. It depends on tolerability, electrolyte management, flavor, reconstitution convenience, packaging, supply reliability, and physician confidence in cleansing performance.

The strongest opportunities are lower-volume preparations, improved taste, ready-to-drink formats, pediatric and medically complex patient segments, and differentiated excipient systems that support new drug applications or 505(b)(2) strategies. Traditional patent protection for the original GoLYTELY formulation is likely limited because the product was approved decades ago and generic PEG-electrolyte solutions are established in the U.S. market.

What excipients are used in GoLYTELY?

GoLYTELY contains PEG 3350 as the osmotic cleansing agent and four electrolytes that reduce net electrolyte exchange during intestinal lavage.

Component	Function	Approximate amount per liter after reconstitution
Polyethylene glycol 3350	Osmotic agent; retains water in the intestinal lumen	236 g
Sodium sulfate	Electrolyte and osmotic contributor	22.74 g
Sodium chloride	Replaces sodium and chloride losses	5.86 g
Potassium chloride	Replaces potassium losses	2.97 g
Sodium bicarbonate	Provides bicarbonate and supports electrolyte balance	6.74 g
Flavor system	Improves palatability	Product-specific
Water	Reconstitution vehicle	Added by patient

The reconstituted solution contains approximately 65 mEq/L sodium, 53 mEq/L chloride, 17 mEq/L sulfate, 5 mEq/L potassium, and 20 mEq/L bicarbonate, according to the U.S. prescribing information.[1]

PEG 3350 is pharmacologically active as an osmotic agent, while the remaining core ingredients function as electrolytes and formulation excipients. The formulation is designed to produce large-volume watery stool while reducing clinically significant shifts in sodium, potassium, chloride, and bicarbonate.

How does GoLYTELY’s excipient system work?

GoLYTELY uses a high-molecular-weight PEG that remains largely within the gastrointestinal tract. PEG 3350 binds water and increases stool volume without relying on active intestinal secretion. The electrolyte blend is intended to approximate an isotonic lavage solution and reduce absorption or excretion of electrolytes during rapid bowel evacuation.[1]

The excipient system creates several commercial constraints:

1. The product requires a large volume of water after reconstitution.
2. The sulfate-containing system can contribute to an unpleasant taste.
3. Flavor performance can deteriorate when the solution is chilled, stored for extended periods, or consumed in repeated doses.
4. The formulation must maintain adequate osmotic activity while avoiding excessive sodium or potassium loading.
5. The final product must remain stable after reconstitution under labeled storage conditions.

The central formulation problem is therefore not simply PEG delivery. It is the balance between cleansing efficacy, patient intake volume, palatability, electrolyte safety, and manufacturing cost.

What commercial opportunities exist for GoLYTELY excipients?

Low-volume PEG-electrolyte formulations

The clearest opportunity is reducing the volume required to achieve adequate cleansing. Conventional GoLYTELY-style preparations require approximately four liters of solution. Lower-volume products can use more concentrated osmotic systems, adjunctive stimulant laxatives, or separate clear-liquid intake.

A reformulated product could target:

• Two-liter PEG-electrolyte regimens
• Split-dose regimens with improved tolerability
• High-concentration PEG systems paired with controlled electrolyte replacement
• Co-packaged supplemental clear liquids
• Ready-to-drink products that remove the reconstitution step

A lower-volume product would compete directly with Plenvu, MoviPrep, Suprep, Clenpiq, and SUTAB rather than with generic GoLYTELY alone.

Taste-masking and flavor systems

Palatability is a major adherence variable. GoLYTELY’s flavor system can be improved through:

• More effective citrus or berry flavor systems
• Reduction of sulfate-associated bitterness
• Sweetener systems with low gastrointestinal impact
• Acidulant adjustment
• Encapsulated or delayed-release flavor components
• Separate flavor sachets supplied with the bowel-prep kit

A flavor system that materially improves completion rates could support a formulation patent or a 505(b)(2) product, provided the sponsor can demonstrate a meaningful clinical or adherence benefit.

The principal design risk is that flavor ingredients must not compromise osmolarity, stability, electrolyte concentration, microbiological quality, or the product’s bowel-cleansing profile.

Ready-to-drink and reconstitution-free formats

GoLYTELY requires the patient or caregiver to add water to a powder. A ready-to-drink product could reduce preparation errors and improve convenience for older adults, caregivers, and patients with limited dexterity.

The commercial barriers are significant:

• Higher shipping weight
• Larger packaging
• Greater warehouse and pharmacy costs
• Microbiological and chemical stability requirements
• More difficult handling after opening
• Increased exposure to container-closure problems

A practical intermediate format is a concentrated liquid requiring dilution to a defined final volume. This approach can reduce package size while preserving dosing flexibility, but it creates a greater risk of patient dilution error.

Pediatric and medically complex formulations

Pediatric bowel preparation remains a potential formulation niche. A pediatric product would need improved taste, lower administered volume, age-appropriate dosing instructions, and packaging that supports weight-based administration.

Other target groups include patients with:

• Chronic kidney disease
• Congestive heart failure
• Electrolyte disorders
• Diabetes
• Dysphagia
• Cognitive impairment
• Prior incomplete colonoscopy preparation

The formulation cannot eliminate the need for medical screening in high-risk patients. A lower-sodium or lower-potassium system could be commercially attractive, but any change to the electrolyte profile would require clinical evaluation and careful labeling.

How does GoLYTELY compare with competing bowel-preparation products?

Product	Core formulation	Delivery form	Commercial positioning
GoLYTELY	PEG 3350 plus sodium sulfate, sodium chloride, potassium chloride, sodium bicarbonate	Powder for approximately four liters after reconstitution	Established high-volume PEG-electrolyte preparation
Generic PEG-electrolyte solutions	Similar PEG-electrolyte systems	Powder for reconstitution	Price competition and pharmacy availability
MoviPrep	PEG-electrolyte system with reduced total volume plus additional clear liquid	Powder for reconstitution	Lower-volume PEG alternative
Plenvu	PEG-based formulation with higher-concentration electrolyte and flavor system	Powder for reconstitution	Lower-volume and palatability positioning
Suprep	Sulfate-based concentrate	Liquid concentrate diluted with water	Small-dose administration plus clear liquids
Clenpiq	Sodium picosulfate, magnesium oxide, citric acid	Ready-to-drink liquid	Convenience and no powder reconstitution
SUTAB	Sulfate-based tablet system	Tablets with water	Avoids drinking large volumes of prep solution

GoLYTELY’s competitive advantage is familiarity, broad clinical use, and a well-established PEG-electrolyte mechanism. Its disadvantages are volume, taste, preparation burden, and direct generic competition.

What patent protection covers GoLYTELY?

GoLYTELY was approved by the FDA under NDA 018735, and the original product has been marketed for many years.[1] Its core composition uses conventional PEG and electrolyte ingredients. Those ingredients are generally difficult to protect through new composition-of-matter patents because they are established pharmaceutical materials.

The likely current protection profile is:

Protection category	GoLYTELY relevance
New chemical entity patent	None expected for PEG 3350
Original formulation patent	Any original patents would be old and unlikely to provide meaningful current exclusivity
Method-of-use patent	Possible only for a narrowly defined clinical use or administration protocol
Flavor patent	Potentially available for a novel taste-masking system
Packaging patent	Potentially available for reconstitution, dosing, or adherence-enhancing packaging
Manufacturing patent	Potentially available for granulation, blending, moisture control, or improved stability
Orange Book protection	Must be assessed against the current FDA Orange Book listing for the specific NDA
Generic blocking position	Primarily dependent on any unexpired listed patents and regulatory requirements

The core GoLYTELY formulation is unlikely to support a strong modern exclusivity position by itself. A new entrant would need to focus on formulation differentiation, delivery format, or clinically meaningful use improvements.

When did GoLYTELY lose exclusivity?

GoLYTELY’s original regulatory exclusivity expired many years ago. The product is not an NCE-era product, and generic PEG-electrolyte solutions are commercially available in the United States.

The commercial protection timeline is therefore different from that of a recently approved branded drug:

Exclusivity or barrier	Current commercial relevance
NCE exclusivity	Expired
Original approval exclusivity	Expired
Generic entry	Already established
Formulation patents	Must be reviewed separately for any active claims
Pediatric exclusivity	No current pediatric exclusivity should be assumed without a specific FDA record
Regulatory switching barrier	Limited because generic PEG-electrolyte products are established

A competitor does not need to wait for a GoLYTELY patent expiry to enter with a substantially equivalent generic product. A differentiated product may use an ANDA if it matches the reference product’s relevant characteristics, or a 505(b)(2) application if it relies on the FDA’s prior findings while introducing meaningful formulation or dosage-form differences.[2]

What is the Orange Book status of GoLYTELY?

The Orange Book is the controlling source for current listed patents and FDA therapeutic-equivalence information. GoLYTELY’s relevant reference product is associated with NDA 018735.[1,3]

For commercial diligence, the key Orange Book questions are:

• Whether the NDA has active listed patents
• Whether any listed patent has a current expiration date
• Whether a generic product is therapeutically equivalent to the reference product
• Whether the branded product remains the reference listed drug for a proposed ANDA
• Whether any patent dispute has been filed after a Paragraph IV certification

Because the original product is old and generic equivalents exist, the primary business risk is unlikely to be an active core-composition patent. The more relevant issue is whether a new formulation creates separate intellectual property around flavor, volume reduction, dosage packaging, or manufacturing.

Which companies are challenging GoLYTELY?

The competitive challenge comes mainly from generic manufacturers and alternative bowel-preparation brands rather than from a single Paragraph IV campaign.

Generic competition can arise through:

• ANDA products directly referencing the PEG-electrolyte solution
• Authorized or private-label versions
• Hospital and pharmacy purchasing contracts
• Regional suppliers with lower acquisition cost
• Products that substitute for GoLYTELY in institutional protocols

Alternative branded competitors include manufacturers of Plenvu, MoviPrep, Suprep, Clenpiq, and SUTAB. These products compete on volume, patient convenience, taste, preparation time, and physician preference.

A Paragraph IV challenge would matter only if the reference product had an unexpired Orange Book-listed patent. For an established GoLYTELY-type formulation, the more likely commercial pathway is ordinary generic substitution or development of a differentiated bowel-preparation product.

What regulatory pathway is available for a new GoLYTELY formulation?

A sponsor has three principal U.S. regulatory strategies.

ANDA pathway

An ANDA is appropriate for a product that demonstrates pharmaceutical equivalence and bioequivalence or meets applicable product-specific requirements. The formulation, dosage form, strength, route, and labeling must align with the reference product, subject to permitted differences.

This pathway is best for low-cost generic entry. It provides limited room for major flavor, volume, electrolyte, or delivery changes.

505(b)(2) pathway

A 505(b)(2) application can support a modified PEG-electrolyte product that relies in part on FDA findings for an approved product but introduces a meaningful change. Potential modifications include:

• New dosage form
• New concentration
• New flavor system
• New administration schedule
• New packaging configuration
• New patient population
• New combination with an established cleansing agent

The sponsor must establish that the changed formulation is safe, effective, and adequately controlled. A 505(b)(2) product may obtain regulatory exclusivity for qualifying changes, even though it does not receive NCE exclusivity.

Full NDA pathway

A full NDA is generally unnecessary for a conventional PEG-electrolyte product unless the sponsor develops a substantially novel formulation, new active combination, or new clinical use that cannot rely adequately on existing FDA findings.

What manufacturing and IP barriers affect GoLYTELY opportunities?

The primary manufacturing barriers are operational rather than chemical.

Raw-material control

PEG 3350 must meet appropriate pharmaceutical quality specifications, including molecular-weight distribution, impurity control, microbial limits, and consistency between lots. Electrolyte salts are inexpensive but must be controlled for identity, assay, particle size, moisture, and contamination.

Powder performance

A successful powder product requires:

• Uniform blending of high- and low-dose ingredients
• Low moisture uptake
• Rapid dissolution
• Limited caking
• Consistent flavor distribution
• Stable packaging during shipping and storage

The large PEG load can create blending and flow challenges. Sachet or bottle packaging must protect the powder from humidity.

Reconstitution and stability

The sponsor must establish the stability of the reconstituted solution, including microbial control, temperature conditions, container compatibility, and storage duration. A ready-to-drink version faces a higher stability burden than a dry powder.

Intellectual property

The most defensible new claims are likely to concern:

• Specific excipient ratios
• Taste-masking combinations
• Reduced-volume electrolyte systems
• Improved dissolution or powder flow
• Moisture-resistant packaging
• Reconstitution devices
• Dosing schedules that improve completion
• Patient-specific or pediatric administration

These claims must be drafted around measurable technical or clinical advantages. Broad claims covering PEG, sodium sulfate, sodium chloride, potassium chloride, and bicarbonate would face substantial prior-art risk.

What revenue exposure does GoLYTELY have?

Public regulatory records establish the product’s approval and composition but do not establish current GoLYTELY-specific revenue. The revenue opportunity is best assessed through market structure:

• Generic erosion limits premium pricing for conventional PEG-electrolyte products.
• Colonoscopy volume supports recurring demand.
• Lower-volume and better-tasting products can command higher reimbursement or cash-pay pricing.
• Hospital and ambulatory surgery center contracts emphasize acquisition cost and supply reliability.
• Products that reduce incomplete procedures or repeat colonoscopies can support economic value arguments.
• Ready-to-drink and tablet products may achieve premium pricing but carry higher manufacturing and distribution costs.

A new GoLYTELY-related product is more likely to create value through differentiated positioning than through protection of the legacy formulation.

How strong is the GoLYTELY patent estate?

The legacy estate appears commercially weak relative to modern branded pharmaceutical products because the active ingredients and electrolyte architecture are established, generic products are available, and the original approval dates to the early U.S. prescription bowel-preparation market.

A new entrant should assess patent strength by claim type:

Claim type	Expected strength
PEG-electrolyte composition broadly	Weak
Narrow electrolyte ratio	Moderate if clinically supported
Taste-masking system	Moderate
Low-volume formulation	Moderate to strong if technically distinctive
Ready-to-drink stability system	Moderate
Packaging and reconstitution device	Moderate
New bowel-preparation regimen	Variable; vulnerable to obviousness challenges
Manufacturing process	Moderate if it solves a reproducible technical problem

Trade secrets may provide more durable protection than patents for blending conditions, flavor premixes, moisture-control processes, and manufacturing specifications.

What generic launch risks exist?

A conventional generic GoLYTELY product faces limited patent risk but meaningful commercial risk.

The principal risks are:

• Price compression
• Established generic suppliers
• Pharmacy substitution dynamics
• FDA manufacturing deficiencies
• Raw-material shortages
• Product recalls
• Poor taste leading to incomplete dosing
• Inconsistent dissolution
• Limited formulary differentiation

A differentiated product faces a different risk profile. The sponsor may obtain stronger pricing but must fund clinical studies, human-factors work, stability programs, packaging development, and market-access efforts.

Key Takeaways

• GoLYTELY uses PEG 3350 with sodium sulfate, sodium chloride, potassium chloride, and sodium bicarbonate.
• Its core formulation is mature and exposed to generic competition.
• The strongest commercial opportunities are lower volume, improved flavor, ready-to-drink delivery, pediatric use, and adherence-focused packaging.
• The likely regulatory options are an ANDA for a conventional equivalent or a 505(b)(2) application for a meaningfully modified product.
• New patent value is more likely in flavor, delivery, packaging, manufacturing, and narrow formulation ratios than in the basic PEG-electrolyte composition.
• Paragraph IV risk is secondary to ordinary generic competition unless current Orange Book records identify an active listed patent.
• Revenue upside depends on differentiation and procedure-completion economics rather than on legacy GoLYTELY exclusivity.

FAQs

Is PEG 3350 in GoLYTELY the same ingredient used in MiraLAX?

Yes. Both products use PEG 3350, but GoLYTELY combines PEG 3350 with a defined electrolyte system and is labeled as a prescription bowel-preparation product. MiraLAX is labeled for occasional constipation and does not use the same electrolyte architecture.[1,4]

Can a company patent a new GoLYTELY flavor?

Potentially. A flavor patent would need to claim a novel and nonobvious flavoring or taste-masking system, usually supported by dissolution, stability, sensory, or adherence data.

Does GoLYTELY have biosimilar competition?

No. GoLYTELY is a nonbiologic small-molecule formulation. Competition is through generic ANDA products and alternative branded bowel preparations, not biosimilars.

Is a lower-volume GoLYTELY product automatically therapeutically equivalent?

No. A lower-volume product with changed concentrations, excipients, administration instructions, or cleansing regimen may require a 505(b)(2) application or other regulatory pathway rather than a conventional ANDA.

What is the most defensible commercial reformulation strategy?

A reduced-volume PEG-electrolyte product with a validated taste-masking system, moisture-protective packaging, simple split-dose instructions, and evidence of improved completion would provide the clearest differentiation from legacy GoLYTELY.

References

1. U.S. Food and Drug Administration. (n.d.). GoLYTELY prescribing information, NDA 018735.
2. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2).
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (n.d.). MiraLAX prescribing information.